1 / 3

Raltegravir

Boc Sciences offers 518048-05-0 Raltegravir in bulk, please inquire us to get a quote for 518048-05-0 Raltegravir.<br>https://www.bocsci.com/raltegravir-cas-518048-05-0-item-84-70289.html<br>

bocsci2018
Download Presentation

Raltegravir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Raltegravir - CAS 518048-05-0 Catalog number: B2693- 070289 Raltegravir is a potent integrase (IN) inhibitor used as an antiretroviral medication for the treatment of HIV infections. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Category Inhibitor Targets Targets HIV Integrase SARS-CoV-2 Molecular Formula Molecular Formula C20H21FN6O5 Molecular Weight Molecular Weight 444.42 Ordering Information Ordering Information Catalo Catalo g g Number Number Siz Siz e e Pric Pric e e Stoc Stoc k k Quantity Quantity

  2. In stoc k B2693- 070289 2 g $198 0 Order Now Bulk Inquiry Chemical Information Chemical Information Category Category Inhibitor Molecular Formula Molecular Formula C20H21FN6O5 Molecular Weight Molecular Weight 444.42 Specification Specification Properties Properties Reference Reading Reference Reading Purity Purity ≥98% Related CAS Related CAS 871038-72-1 (Potassium) Appearance Appearance Light Beige Solid Synonyms Synonyms Isentress; MK-0518; MK 0518; MK0518 Clinical Trial Information Clinical Trial Information NCT Number NCT Number Title Title Condition Condition Or Disease Or Disease Phase Phase Start Start Date Date Sponsor Sponsor Status Status NCT00105157 Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected HIV Infections Phase 2 March 2005 Merck Sharp & Dohme Corp. Completed

  3. Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) NCT00369941 A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) HIV Infections Phase 3 August 2006 Merck Sharp & Dohme Corp. Completed NCT00377065 Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) HIV Infections Merck Sharp & Dohme Corp. Approved for marketing NCT00443703 MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518- 032)(TERMINATED) HIV Infection Phase 3 May 2007 Merck Sharp & Dohme Corp. Terminated NCT00515827 Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load HIV Infections Phase 2 November 2007 National Institute of Allergy and Infectious Diseases (NIAID) https://www.bocsci.com/raltegravir-cas-518048-05-0-item-84-70289.html

More Related